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Chlamydia has a signiﬁcant impact on public health provision in the developed world. Using pair approximation equations we
investigate the eﬃcacy of control programmes for chlamydia on short time scales that are relevant to policy makers. We use output
from the model to estimate critical measures, namely, prevalence, incidence, and positivity in those screened and their partners.
We combine these measures with a costing tool to estimate the economic impact of diﬀerent public health strategies. Increasing
screening coverage signiﬁcantly increases the annual programme costs whereas an increase in tracing eﬃciency initially increases
annual costs but over time reduces costs below baseline, with tracing accounting for around 10% of intervention costs. We found
that partner positivity is insensitive to changes in prevalence due to screening, remaining at around 33%. Whether increases occur
in screening or tracing levels, the cost per treated infection increases from the baseline because of reduced prevalence.
1.Introduction
Infection with Chlamydia trachomatis is a problem for
infected individuals and health services. Chlamydia is the
most prevalent sexually transmitted infection (STI) in the
UK [1], with a large proportion of cases asymptomatic,
and untreated infection can lead to serious complications
for men and women. Men can develop epididymitis as a
result of infection, while untreated chlamydia in women can
cause pelvic inﬂammatory disease (PID), ectopic pregnancy,
and tubal factor infertility [1]. A randomised control trial
in the USA found that screening for chlamydia reduced
the incidence of PID by 56% [2]. Treatment of chlamydia
is straightforward, and front-line therapy is a single dose
of azithromycin which is eﬀective at clearing chlamydia
and has recently been approved by the Medicines and
Healthcare products Regulatory Agency (MHRA) for use
without prescription [3]. The problems caused by chlamydia
are estimated to cost the National Health Service (NHS) in
England over £100m every year [3] and cause morbidity in
some individuals.
In England in 2003 the National Chlamydia Screening
Programme (NCSP) was set up; central to its mission was
reducingtheonwardtransmissionofgenitalchlamydiainfec-
tion and preventing sequelae through early detection [1].
The NCSP targets young persons under 25 years outside of
sexual health clinics, screening individuals opportunistically
when they visit other health services [4]. Prevalence of
chlamydia is highest among young people, with those under
25 most likely to be infected [5]. Screening an individual is
a quick, easy, noninvasive process, and if someone is found
to be infected, an eﬀort is made to oﬀer a screen to their
previous sexual partners [4]. Thus contact tracing forms an
integral part of the NCSP, working alongside opportunistic
screening. In 2009 the NCSP tested 16% of young people
aged 15–24 years [4] compared to a target of 17% for that
period.Longer-termgoalsaretoachieveascreeningcoverage
of 35%–50% [3], although it is uncertain how long it will
taketoachievethesegoalssinceincreasingnationalscreening
coverage is complex. However, there are uncertainties about
the eﬀects and the cost eﬀectiveness of the programme [6].
The question that we wish to address is the following: how2 Computational and Mathematical Methods in Medicine
will achieving these targets impact on prevalence, incidence,
andpositivitywithinthetimescalesusedtodeterminepolicy
decisions (taken to be up to ﬁve years)?
Diﬀerent modelling approaches have been used for
chlamydia and other similar infections such as gonorrhea.
Two aspects stand out as important in STI modelling:
heterogeneity in the sexual activity of the population [7]a n d
thestronginﬂuenceofsocialstructureonepidemicdynamics
[8]. Unlike airborne diseases, STIs can only be spread as
a result of clearly deﬁned sexual interaction, and hence
random mixing assumptions used in more basic models fail
to capture an important aspect of STI transmission. Previous
work by Anderson and May [9] ,H e t h c o t ea n dY o r k e[ 10],
and others [11, 12] has used mean-ﬁeld ordinary diﬀerential
equations (ODEs) to look at the spread of HIV/AIDS,
gonorrhea, and chlamydia. In these models heterogeneity
between individuals has been incorporated through the use
of a “core” group which is small in size but high in sexual
activity, sustaining disease in a population where it would
otherwise be eradicated. Although easier to analyse, these
models are too simple to model contact tracing eﬀectively.
Studies informing public health policy have often used
large individual-based stochastic simulations [7, 13–15]. In
these simulations it is possible to track the behaviour of
eachindividualandhenceimplementcontrolpoliciesexactly
as conceived. However, these models also require a large
number of parameters to be estimated, and in the case
of chlamydia these are not always known accurately. For
example, transmission probabilities and natural clearance
rates are subject to some uncertainty since they cannot be
studied easily. The three models compared by Kretzschmar
et al. all assume a transmission probability per sex act, even
though previous work [16] has shown that the number of
sexual exposures to an infected partner does not correlate
with infection status. The relative eﬀectiveness of screening
and contact tracing has been examined for a general disease
on random networks [17], and it has also been shown that in
a general SIS model there is a critical prevalence below which
contact tracing becomes cost eﬀective [18].
Pair approximation equations have been successful in
bridging the gap between stochastic network simulations
and mean-ﬁeld ODE models [8, 19–22]. They model how
the number of pairs of a certain type varies with time,
as well as the number in each class of individuals. The
equations for the number of pairs involve the number of
triples,butinsteadofformingthetriple equationsthesystem
is usually closed at the level of pairs using a moment
closureapproximation[23,24].Thesemod elsaimt ocaptur e
the inﬂuence that network structure has on the spread of
disease but without actually modelling speciﬁc individuals.
Pair models are appropriate here because they have a lot
fewer parameters than individual-based models but can
still capture the network behaviour necessary for disease
transmission and contact tracing.
Of particular relevance, Eames and Keeling [8]a n d
House and Keeling [25] modelled the spread of STIs in a
closed population to explore the eﬃcacy of contact tracing.
They investigated the relationship between critical tracing
eﬃciency (eﬃciency needed to prevent invasion of the
disease) and the basic reproductive number R0, ﬁnding that
R0 can be used to estimate critical tracing eﬃciency and that
clustering in the network improves the eﬃcacy of contact
tracing.
The aim of this study is to use pair approximation
equations to capture the essence of network dynamics in a
set of ODEs and use these to measure the impact of diﬀerent
controlstrategiesforchlamydiaonrealistic,shorttimescales.
We investigate outcomes linked to positivity, prevalence,
incidence, and cost, showing how control programmes may
aﬀect directly observable quantities.
2.Methodology
Our model is developed from previous work [8, 25]
restricted to a target population in the 16–25-year age
bracket. The population is assumed to be of constant
size N following [26]; this is a reasonable assumption
since recovered individuals return to the susceptible pool
(possibly following a period of immunity) and since we
are only concerned with a ﬁve-year time frame. Susceptible
individualsbecomeinfectedeitheriftheyareinapartnership
with an infected individual or if they are in a partnership
withasusceptibleindividualbuthavecontactexternaltothat
partnership with an infected individual. The rate at which
infection happens is β. Once infected, an individual may
move into the treatment class either because they develop
symptoms naturally at rate d o ra sar e s u l to fb e i n gs c r e e n e d
at rate g. Infected individuals may clear infection without
treatmentandreturntothesusceptibleclasswhichtheydoat
rater<d . Partner notiﬁcation (PN) also means that infected
individuals may move into the treated class if they are in
a partnership with an individual in the treatment class and
they do so at a rate c. Assuming that treatment is successful,
individuals return to the susceptible class at rate a.T h i sg i v e s
rise to the model system:
 ˙ S

=− β[SI]+a[T]+r[I],
˙ I

= β[SI] −

g +d +r

[I] −c[IT],
 ˙ T

=

g +d

[I]+c[IT] −a[T],
(1)
where [S], [I], and [T] denote the number of individuals
in each of the classes susceptible, infected, and treated,
respectively, and where [SI] denotes the number of partner-
ships in which one individual is susceptible and the other
infected, and so forth. A ﬂowchart of the system is shown
in Figure 1. To fully specify the model, we need to write
down the time evolution equations for each pair; these are
given in Appendix A where it can be seen that they involve
the parameter k which measures the average number of
partnershipsperindividual.Baselineparameterestimatesare
derived from published data and are given in Table 1.T h e
infection rate across an S-I link (β) is estimated by keeping
all other parameters constant and then setting β to achieve a
steady-state prevalence of 8%.
We investigate how changes in the control parameters (c
and g), assumed to be independent of each other, impact
on prevalence, incidence, and positivity. Each measure isComputational and Mathematical Methods in Medicine 3
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Figure 1: Flowchart of the model system.
calculatedfortheﬁrst,third,andﬁfthyearafterastepchange
in the control parameters. In the deﬁnitions below ti is the
day at which the ith year begins: for example, if a step change
in c is at t = 0, then t3 = 2 ∗365 = 730.
Prevalence. This is given by the proportion of individuals
infected and is calculated using the value at the end of the
year in question by
[I]+[T]
N
(ti). (2)
Positivity. We consider two measures of positivity.
(i) Individual positivity. Here we assume that peo-
ple undergoing treatment in the T c l a s sw i l ln o t
be screened, so this is diﬀerent from population
prevalence. Positivity is perhaps the most important
quoted statistic for a screening programme such as
the NCSP. It is calculated as
1
365
 ti+1
ti
[I]
[S]+[I]
dt. (3)
(ii) Partner positivity. The equivalent “positivity” mea-
sure for contact tracing is deﬁned as an average over
a year (as above) of the proportion of contacts of T
individuals who are infected, given by
1
365
 ti+1
ti
[IT]
[ST]+[IT]
dt. (4)
Once again the assumption is that if the partner of
a T individual is also a T, then no eﬀort will be
expended in tracing them. This measure is important
for analysing how correlated infectious individuals
are with other infected people and how much more
likely you are to ﬁnd an infected individual through
contact tracing instead of screening.
Incidence. This is deﬁned as the number of new cases in a
given year and is given as cases per 10000 person-years. It is
important to ensure a good match between model and real
incidence, as well as estimated prevalence, as incidence gives
an indication of disease turnover which will impact on the
eﬃcacy of control measures [13]. It is calculated as
 ti+1
ti
β[SI]dt. (5)
The number of partners per individual, k, was set using
ﬁgures calculated in [27], which is based on estimates
from NATSAL 2000. This is the National Survey of Sexual
Attitudes and Lifestyles, a survey carried out in Great
Britain between 1999 and 2001, which looked at the sexual
behaviour of people aged between 16 and 44 [30]. The
screening parameter g is calculated from the percentage of
the population who is screened over a period of one year.
This allows the parameter to be compared directly with
ﬁgures published by the NCSP. If a proportion s of the
population is screened per year, g can be calculated using
s = 1 − e−365g. (6)
Tracingsuccessismeasuredasc/a,theproportionofpartners
traced.
The rate of naturally developing symptoms (d)i sg i v e n
by assuming that some small fractions of those becoming
infected go on to be symptomatic (20% in this case) and that
if they do, then they do so quickly with an average time spent
infected of 30 days [12, 14].
We obtain values for the measures listed above from
numerical simulations of the model system. We run the
system to equilibrium and then make a step change in either
c or g and record the new values for each measure one,
three and ﬁve years following that change. More realistically
there would be a gradual change over a period of time,
which means that our results provide an upper bound on the
possible impact.
In addition, we use a published costing tool [31]t o
explore the economic impact of changing levels of screening
or partner notiﬁcation. Since resources are limited, decisions
mustbemadeonhowtosharethesebetweenactivitieslinked
to screening individuals and activities focussed on contact
tracing. We explore this interdependence by numerically
solving the system to ﬁnd the tracing eﬃciency that gives
the speciﬁed target prevalence after 3 years, for diﬀerent
screening coverages. For a speciﬁed screening coverage,
we calculate the level of tracing needed to reach target
prevalence. All numerical results in this work were obtained
using MATLAB.
3. Results
In each of the following ﬁgures we show the baseline case
(where the system is at steady state with annual screening
coverage of 16% and tracing eﬃciency of 30%) along with
the results from changing the control parameters.
In Figure 2 changes in prevalence (Figures 2(a) and
2(b)) and incidence (Figures 2(c) and 2(d)) are shown,
where screening coverage is increased to 20%, 25%, 35%, or
50% and tracing eﬃciency is increased to 35%, 40%, 50%,
or 60%. Assuming that screening and partner notiﬁcation
rates can be varied independently, our results are consistentComputational and Mathematical Methods in Medicine 5
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Figure 2: Prevalence (top) and incidence (bottom) after speciﬁed changes to tracing eﬃciency (left) and annual screening coverage (right)
in parameters where baseline prevalence is 8%. Prevalence ﬁgures are broken down into those in the I and T classes.
with previous work, but the novelty here lies in our focus
on short-term behaviours. In every situation the size of
the treatment class remains essentially unchanged for at
least three years, after which it decreases in size. Screening
and partner notiﬁcation both have similar impacts, causing
reductions in overall prevalence and incidence.
Baseline incidence levels in Figure 2 compare favourably
with those in large individual-based models. Kretzschmar
found that incidences in the models being compared were
between 500 and 4000 cases per 10000 person-years [13],
while Batteiger recently found that incidence in a real world
study was around 3400 cases [32]. The ﬁgure here of 2500
cases is most similar to that given by the HPA model [13, 14],
which has ﬁgures between 1000 and 2000 depending on age
range. As expected, the incidence follows a similar pattern
to that for prevalence, with screening levels at 50% per year
or tracing eﬃciency at 60% able to signiﬁcantly reduce the
number of new cases in the population after ﬁve years. An
increase incontacttracing hasmore of aneﬀectoverthelong
term compared to screening, although over a shorter period,
the eﬀects are similar (Figure 2).
Figure 3 shows the values of individual positivity and
partner positivity in a similar way, except that values are
shown as points instead of bars instead of bars. Posi-
tivity (both individual and partner) provides the clearest
indication of where screening and contact tracing will be
most eﬀective. Figure 3 shows individual (Figures 3(a) and
3(b)) and partner positivity (Figures 3(c) and 3(d)), and
as expected individual positivity is similar to prevalence
since only a relatively small proportion of people are
in the treatment class at any one time, and it is only
these people who will not be available for a random
screening programme. Partner positivity is a diﬀerent story;
screening and contact tracing do not massively aﬀect the
chance of ﬁnding an infected individual in a partnership
with somebody receiving treatment (partner positivity),
with values starting at 36% and remaining close to 30%
even after ﬁve years of increased control eﬀorts. This6 Computational and Mathematical Methods in Medicine
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Figure 3: Individual (top) and partner (bottom) positivity after changes to tracing eﬃciency (left) and annual screening coverage (right) for
a baseline prevalence of 8%.
contrasts with individual positivity that starts at a baseline
value of just over 6% and then falls away with amounts
depending on how much control is being implemented.
This is important for comparing the eﬀectiveness of the
two measures, since the lower the prevalence, the greater
the relative chance of ﬁnding another infected individual
through contact tracing instead of screening. As prevalence
increases, the eﬀectiveness of screening will be increased
while that of contact tracing will remain roughly simi-
lar.
3.1.FinancialCosts. UsingthetooldevelopedbyTurneretal.
[31], preliminary cost analysis is presented in Table 2. This
highlights the dependency between screening and partner
notiﬁcation, showing that as prevalence decreases, cost per
infectionwillincrease.Thiswouldbeexpectedforasituation
where there is a large control eﬀort (with large cost)
that continues regardless of prevalence. We focus soley on
the output generated by the tool in question in order to
demonstrate that dynamic models can be combined with
existing tools to improve their accuracy.
Increasingtracingeﬃciencyto40%incursacostincrease
of around £1m in the ﬁrst year, with a cost per treated
infectionof£660.92comparedtothebaselinecaseof£633.26
per infection. After three years, costs have been reduced
to below the baseline value, but now the cost per treated
infection is £847.77 because prevalence has been reduced
from the baseline value of 8% to 5.3%. Increasing screening
coverage to 25% represents a large increase in total annual
costs of about £25m, with a cost per infection treated in the
ﬁrst year of £665.89. This is larger than the cost per infection
in the ﬁrst year when tracing eﬃciency is increased, and
prevalence is higher in the screening case (7.3% compared to
7% for tracing). After three years with increased screening,
coverage total costs are still about £25m above the baseline
case, with a cost per infection of £775.29. This is less than
the cost per infection after three years of improved tracing,
but prevalence is 6.3% compared to 5.3% with tracing.
Overall, the cost eﬀectiveness of increasing contact tracingComputational and Mathematical Methods in Medicine 7
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Figure 4: Tracing eﬃciency required for speciﬁed screening
coverage in order to achieve target prevalence of 2%, 4%, and 6%
after three years.
eﬃciency compared to screening coverage is clear, with
greater reductions in prevalence for less cost.
3.2. Interdependence. In reality, the amount of screening
and/or partner notiﬁcation that one is able to carry out
will depend on how limited resources are allocated between
the two. In Figure 4 we show how diﬀerent combinations
of screening and partner notiﬁcation will achieve the same
target prevalence after three years. Each line shows combi-
nations of tracing eﬃciency and screening coverage that will
achieve a prevalence of 2%, 4%, or 6% after three years, from
a baseline of 8% prevalence.
3.3. Robustness of Results. A sensitivity analysis was per-
formed on the model, with outputs given by varying model
parameters a, d, r,a n dk by ±10%. For ﬁgures and more
details, see Appendix B. Our results prove robust to these
changes in parameters, with the most signiﬁcant eﬀect seen
in the impact on contact tracing when k, the average number
of connections per individual, is varied. This is as one would
expect, since tracing is heavily dependent on the network
structure, but even so the variation is small and does not
aﬀect the conclusions of this work.
4. Discussion
Using a deterministic set of pair approximation equations we
have explored the eﬀect of increasing screening or contact
tracing levels over time scales relevant to policy makers.
This relatively simple model has been applied to chlamydia
infection and treatment, with the model parameters largely
takenfromtheliterature.Althoughtheoreticalworkhasbeen
done on a similar model [25], we have studied the short-
termimpactofchangesincontrolstrategyandlookedathow
the system behaves dynamically. Partner positivity has been
deﬁned in terms of this model, and we have demonstrated
that this measure stays relatively unchanged even when
prevalence and individual positivity are decreasing. Partner
positivity is insensitive to changes in screening coverage
or tracing eﬃciency, remaining at around 33%. This is
important when considering how best to target a control
programme,sinceourresults,alongwithpreviouswork[18],
suggest that there is a critical prevalence below which contact
tracing is advisable.
In addition, we have linked our dynamic results with a
previously published costing tool which is used by health
care providers [31]. This highlights the cost eﬀectiveness of
increasing tracing eﬃciency instead of screening coverage
when the underlying model is not static. Combining this
analysiswiththeinterdependenceresultsinFigure4provides
a means for estimating the most cost-eﬀective strategy
combination for achieving a target prevalence in a certain
time frame. Since the costs of partner notiﬁcation are an
order of magnitude less than screening, and PN has a
greater chance of success, it is important that any control
programme pursues the partners of any index case. Further
work will explicitly model the resource limitations inherent
in a public health programme and identify how best to
distribute the resources across screening and tracing.
Eﬀorts have been made to use accurate parameters
based on available data, but there is still a great deal of
uncertainty around some critical quantities, for example,
how fast individuals recover without any treatment or how
much immunity someone has after clearing infection nat-
urally. However, our sensitivity analysis has shown that the
conclusions remain valid under a wide range of parameter
values. There is some scope for extending this approach to a
heterogeneous population by having individuals with diﬀer-
ent numbers of partners, either by having them incorporated
into one population and modelling every permutation of
diﬀerent types of connection or by having several diﬀerent
homogeneous populations with links between.
In the meantime, by using the approach detailed here,
comparisons can be made that will, at the very least, provide
qualitative and order of magnitude quantitative information
about changes in intervention strategies for chlamydia.
Appendices
A. Model Equations
T h ef u l ls y s t e mo fm o d e le q u a t i o n si s
 ˙ SS

= 2a[ST]+2 r[SI] −2β[SSI],
 ˙ SI

= β([SSI] −[ISI] − [SI]) −c[SIT]+a[IT]
−

g +d +r

[SI]+r[II],
 ˙ ST

=

g +d

[SI]+a[TT] −β[TSI]+c[SIT] −a[ST]
+r[IT],
 ˙ II

= 2β([SI]+[ISI]) −2c[IIT] − 2

g +d +r

[II],
 ˙ IT

= c([IIT] −[IT] −[TIT]) −

g +d +r +a

[IT]
+β[TSI]+

g +d

[II],
 ˙ TT

= 2

c +g +d

[IT]+2 c[TIT] −2a[TT].
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Figure 5: Maximum relative %d i ﬀerence from baseline for each
parameter, when screening coverage is increased to 25% or tracing
eﬃciency to 40%.
These equations contain terms involving the number
of triples of certain types, where [ABC]r e p r e s e n t saC
individual connected to an A-B pair. Equations for pairs
involving two individuals of the same type (e.g., [TT])
contain factors of two because they represent links in both
directions across (T-T) partnerships, whereas other pair
equations (e.g., S-I) only represent one direction (not I-S)
but their counterparts are not modelled explicitly because
they evolve in exactly the same way. To close the system we
must express triples in terms of pairs; to do this we assume
that pairs are independently binomially distributed so that
[ABC] =
k −1
k
[AB][BC]
[B]
,( A . 2 )
where k is as described in Table 1. Individual class sizes
can be recovered from the pair structure using the following
expressions:
[S] =
1
k
([SS]+[SI]+[ST]),
[I] =
1
k
([SI]+[II]+[IT]),
[T] =
1
k
([ST]+[IT]+[TT]).
(A.3)
We use this to simplify the model to the six-dimensional pair
system (A.1).
B.SensitivityAnalysis
T h e r ei ss o m eu n c e r t a i n t yi nt h en u m e r i c a lv a l u e so fm o d e l
parameters; in order to assess the impact of this, we varied
a, d, r,a n dk by ±10%, adjusted β to maintain the initial
prevalence, and compared model outcomes to our baseline
case. Varying the parameters in this way gives suﬃciently
large coverage of the parameter space, to verify robustness
of model outputs. For each parameter varied, we looked
separately at increasing screening to 25% per year and also
increasing tracing eﬃciency to 40%.
Figure 5 shows the results for increasing screening
coverage to 25% and also for when tracing eﬃciency is
increased to 40%. For each parameter (a, d, r,o rk), Figure 5
gives the maximum relative percentage diﬀerence from the
baseline values of I and T after 0, 1, 3, or 5 years. The case at
0 years is included because although the starting prevalence
is always 8%, the split of infected persons between the I and
T classes changes with diﬀerent parameter sets.
Overall, we see that the results are very robust to changes
in parameters. The maximum relative diﬀerence is around
10%, so if we assume the worst-case scenario, and prevalence
is 8%, then this would result in an absolute change in
prevalence of 0.8% over 5 years. We see that for a, d,a n d
r, the screening and tracing results are both aﬀected roughly
equally, with r making the least diﬀerence. Changes in the
size of k have a much larger eﬀect on the results when tracing
eﬃciency is changed than screening coverage (although this
is still small). This is as expected because the eﬀectiveness
of tracing depends crucially on how many partners each
individual has.
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